



## Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
April 20, 2023	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[\\* Click HERE for Meeting Documents \\*](#)

<u>Board Members Present</u>	<u>MO HealthNet Staff Present</u>	<u>Contractors Present</u>
Kimberly Eisenstein, MD Lisa Pierce, MD Jennifer Passanise, FNP-BC Stacy Mangum, PharmD Ginger Nicol, MD, CEDS Rick Kegler, PharmD Charlene Hyde, PharmD Sandra Bollinger, PharmD Julie Ferguson, DO	Angela Wilson, Pharmacy Operations Manager Carmen Burton, Pharmacy Support Assistant Connie Sutter, Fiscal Manager Elizabeth Short, Program Development Specialist Elizabeth Sissom, RN, Clinical Review Nurse Joshua Moore, PharmD, Director of Pharmacy Danielle Dodd, Special Counsel Lisa Smith, Pharmacy RFP Coordinator Mark Roaseau, R.Ph., Clinical Pharmacist Nikki Ashley, Pharmacy Program Specialist Olivia Rush, PharmD, Program Integrity Pharmacist Timothy Kling, MD, Acting Medical Director	Amanda Williams, PharmD, RPh, GWT Chelsea Pendleton, RN, BSN, Wipro Dimple Patel, PharmD, Conduent Jennifer Colozza, PharmD, Conduent John Crowley, PharmD, BCPS, CPPS, Conduent Karen Powell, PharmD, MS, GWT LeAnna Kirsch, RN, Wipro Lynn Morsches, PharmD, Conduent Mandy Nilges, RN, Wipro Megan Fast, PharmD, GWT Sandy Kapur, PharmD, GWT Serena Barden, PharmD, BCPS, GWT
<u>Board Members Absent</u>		

### Others Present:

Drug Utilization Review Board Meeting – April 20, 2023

Amanda Nowakowski

Clemice Hurst

Daphne Ni

Dennis Murphy

Emma Andelson

Eric Peters

Heather Fremi

Jeff Knappen

Jenny Carrell

Jessica Petrie

JJ Roth

John Bullard

Jomy Joseph

Jonathan Leesman

Kenneth Berry

Kim Witte

Kimbra Brooks

Lee Ward

Marc Parker

Matt Baker

Megan Kricsfeld

Nancy Mosier

Richie Crawford

Ricki Roberson

Rob Kilo

Rob Picone

Robin Selsor

Sara Hovland

Waleed Al-Homoud

Zach Thomas

<b>Welcome, Announcements and Introductions</b>	Joshua Moore, MHD Director of Pharmacy, called the meeting to order, introduced himself and facilitated the meeting on behalf of the MO HealthNet Division.
<b>Minutes Review</b>	<p><b>Discussion:</b> Minutes were reviewed from the January meeting.</p> <p><b>Decision:</b> The Board voted to accept these approved minutes with no revisions.</p>
<b>Pharmacy Program and Budget Update</b>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> <li>- February 2023 Enrollees and Expenditures</li> <li>- July 2022 – February 2023 Expenditures by Service</li> <li>- FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures</li> <li>- February 2023 Medicaid Expansion Participants, Expenditures, and Claim Count</li> <li>- FY19 to FY23 Mavyret Expenditures</li> <li>- CY2023 Per User Per Month Drug Claim Reimbursement</li> <li>- March 2023 Top Ten Reimbursed Drugs</li> <li>- March 2023 Top Ten Reimbursed Drugs for Children 0-17</li> <li>- Additional updates were provided on: <ul style="list-style-type: none"> <li>o Clinical Initiatives: <ul style="list-style-type: none"> <li>▪ Project Hep Cure – selected to receive the 2022 Governor's Award for Quality and Productivity in the category of Innovation</li> <li>▪ 15 Day Psychotropics Edit retirement</li> <li>▪ Decreasing unnecessary faxes</li> <li>▪ CGM Edit – increased look back for insulin</li> <li>▪ DUR messaging</li> </ul> </li> <li>o Reminder that pharmacists attending the meeting are eligible for continuing education</li> <li>o Current and Future Challenges – Drug Pricing</li> <li>o Accelerated approval pipeline products and cost to the state</li> <li>Autofill regulation</li> </ul> </li> </ul>

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: <a href="https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm">https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</a></p>
New Business	
New Drug Review	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> <li>o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action.</li> </ul> </li> <li>- No other discussion.</li> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>o Matt Baker with Axsome Therapeutics on Auvelity</li> </ul> </li> </ul> <p><b>Decision:</b> The Board voted to accept the presented new drug recommendations with no revisions.</p>
Election of New Chair	<p><b>Discussion:</b> A motion was made by Stacy Mangum and seconded by Rick Kegler to elect Kim Eisenstein as the new Board Chair. Kim accepted the motion.</p> <p><b>Decision:</b> The Board voted to elect Kim Eisenstein as the new Board Chair.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> <li>o Acne or Rosacea, Select Topical Agents</li> <li>o Fabry Disease</li> <li>o Givlaari</li> <li>o Imcivree</li> <li>o Isturisa</li> <li>o Megestrol</li> <li>o Nulibry</li> <li>o Oxervate</li> <li>o Oxlumo</li> <li>o Scenesse</li> <li>o Sickle Cell Disease</li> <li>o Spravato</li> <li>o Systemic Antifungals</li> <li>o Tavneos</li> <li>o Voxzogo</li> <li>o Zokinvy</li> <li>o Zulresso</li> </ul> </li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions, recommending Givlaari be sent back to the Rare Disease Advisory Council for further review.</p>
Hemgenix Clinical Edit	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center"><b>Tzield Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center"><b>Preferred Drug List Edit Review</b></p>	
<p align="center"><b>Preferred Drug Edits With No Annual Changes</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edits for discussion to the Committee which included:             <ul style="list-style-type: none"> <li>o Actinic Keratosis Agents, Topical</li> <li>o Androgenic Agents</li> <li>o Antibiotics, Inhaled</li> <li>o Anticholinergics, LABA Combinations</li> <li>o Anticholinergics, Short Acting and Combinations Inhaled</li> <li>o Antifungals, Topical</li> <li>o Antihistamines &amp; Antihistamine/Decongestant Combinations, 2nd Generation</li> <li>o Antihistamines, Intranasal</li> <li>o Antiparasitics, Topical</li> <li>o Antivirals, Herpes Oral</li> <li>o Benzoyl Peroxide/Antibiotic Combinations</li> <li>o Beta Adrenergic Agents, Nebulized</li> <li>o Beta Adrenergic Agents, Short Acting</li> <li>o Corticosteroids, Ophthalmic Soft</li> <li>o Corticosteroids, Oral Inhaled</li> <li>o Corticosteroids, Topical</li> <li>o Cough/Cold Preparations</li> <li>o Fluoroquinolones, Ophthalmic</li> <li>o Fluoroquinolones, Otic</li> <li>o Hepatitis C Agents</li> <li>o Leukotriene Receptor Modifiers</li> <li>o Mast Cell Stabilizers, Ophthalmic</li> <li>o NSAIDs, Ophthalmic</li> <li>o Pancreatic Enzymes</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>○ Retinoids, Topical</li> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>○ Heather Freml with Abbvie on Mavyret yielded time back</li> </ul> </li> </ul> <p><b>Decision:</b> The Committee voted to accept the recommended criteria with no additional revisions.</p>
<b>Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Anticholinergics, Long Acting Inhaled</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Antifungals, Oral</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Antihistamines, Ophthalmic</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Antivirals, Topical</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

<b>Beta Adrenergic Agents, Long Acting</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Corticosteroids &amp; Rhinitis Agents, Intranasal</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Epinephrine Agents, Self-Injectable</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Glaucoma Agents</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Inflammatory Bowel Disease Agents, Oral</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>



<b>Inflammatory Bowel Disease Agents, Rectal</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with the proposed change.</p>
<b>Other Business</b>	
<b>Program Utilization Information – Conduent Update</b>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Top 25 Drugs by Paid Amount 2<sup>nd</sup> Quarter SFY23 (October, November, December)</li> <li>- Top 25 Drugs by Paid Number 2<sup>nd</sup> Quarter SFY23 (October, November, December)</li> <li>- Call Center Helpdesk Status Report February 2023</li> <li>- SmartPA Transparency Report</li> </ul>
<b>RetroDUR Update</b>	<p>Dimple Patel with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Recent RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Continuous Glucose Monitors (GCM)</li> </ul> </li> <li>- Outcome Assessment: <ul style="list-style-type: none"> <li>o Concurrent Opioids and Benzodiazepines</li> </ul> </li> <li>- Potential RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Long-acting Injectable (LAI) Antipsychotic Use in Schizophrenia</li> </ul> </li> <li>- Other RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Gabapentin Dose</li> </ul> </li> </ul>
<b>Motion to Close</b>	Rick Kegler motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.
<b>Executive Session</b>	MO HealthNet data analysis was reviewed with the Board during Executive Session.

**NEXT MEETING: Thursday, April 20, 2023**  
615 Howerton Court, Conference Room 202  
Jefferson City, MO 65109 and WebEx

Roll Call for April 20, 2023					
	<u>Action Item</u>				
<u>Board Member</u>	January Meeting Minutes	All Recommendations: Block Vote for New Drug, CE, FE and PDL Edits	Election of New Chair	Closing	Adjournment
Charlene Heyde	SY	Y	Y	Y	Y
Ginger Nicol	Y	Y	Y	Y	Y
Jennifer Passanise	Y	Y	Y	Y	Y
Julie Ferguson	Y	Y	Y	Y	Y
Kim Eisenstein	MY	SY	Y	Y	MY
Lisa Pierce	Y	Y	Y	Y	Y
Rick Kegler	Y	Y; AB Vozxogo CE	SY	MY	SY
Sandra Bollinger	A	Y	Y	Y	Y
Stacy Mangum	Y	MY	MY	SY	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain